Reviews/Omega-3 Fatty Acids/Omega-3 reduces preterm birth
Preg · OMEGA-PREG-01 · v2
Taken together, the studies here do not show that omega-3 in pregnancy reliably lowers preterm birth for women in general. The largest and most careful trial found no overall effect; it only helped women who started pregnancy low in omega-3, and appeared to raise risk in women who already had plenty [1][3][4]. A recent placebo-controlled trial found no benefit either [10]. Some studies did report positive results, but only in narrow groups such as smokers [8], or used weaker designs that measured length of pregnancy rather than preterm birth itself [5], or could not rule out other explanations [9]. The panel therefore treated the benefit as conditional on who is being treated, not as a general rule.
The best-powered, double-blind trial (ORIP) showed no overall reduction in preterm birth; the reduction was confined to women with low baseline omega-3 status (early preterm birth RR 0.23 [1]; OR 0.30 [3]), and the same analysis found increased early preterm birth in replete women (RR 2.27 [1]). Among compliers the effect on preterm birth was 0.76 but early preterm birth remained non-significant (0.80) [4]. A recent placebo-controlled trial was null for a composite including preterm birth ≤34 weeks (RR 1.17 [10]). Supportive signals are narrow: benefit in smokers only (RR 0.56 vs 1.04 in nonsmokers [8]), an open-label trial reporting longer gestation (38.2 vs 36.6 weeks [5]), and an observational cohort (aOR 0.64 [9]) whose authors flag residual confounding. The contested point: The division is over whether a benefit exists at all for the general population versus only in conditional subgroups. The positive results all sit in biomarker-defined, behaviour-defined, or design-limited strata [1][3][8][5][9], while the two most rigorous analyses are null overall [4][10].
All 10 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Omega-3 Fatty Acids, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The largest and most rigorous trial (ORIP, N=5328, double-blind) found no overall effect; benefit is confined to the low baseline omega-3 status subgroup [3][4] and the same analysis shows harm in replete women (RR 2.27) [1]. The unqualified claim overreaches a conditional, biomarker-dependent effect.
A recent placebo-controlled RCT (DEEPER [10]) was null for a composite including preterm birth ≤34 weeks (RR 1.17, 95% CI 0.55-2.50); even allowing for being underpowered, it provides no positive evidence.
Where it remains uncertain. The same trial that supports a low-status benefit [1] shows harm in replete women (RR 2.27), and remaining positive signals are subgroup-restricted [8], open-label with a surrogate endpoint [5], or observational [9].
Aleatory
Preterm and early preterm events are rare, so subgroup estimates carry wide intervals (e.g. EPTB RR 0.23, CI 0.07-0.79 [1]; composite RR 1.17, CI 0.55-2.50 [10]) and DEEPER observed fewer events than expected [10].
The load-bearing papers from a corpus of 10, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Shows a strong reduction in early preterm birth but only in the low-baseline-status subgroup.
“Supplementing women with a baseline status above 4.9% increased early preterm birth (2.20 versus 0.97%; relative risk = 2.27, 95% CI 1.13-4.58).”
Panel auditInternal validity: medium · scope of inference: Women with singleton pregnancies in the ORIP trial, distinguishing those with low versus high baseline omega-3 status; outcome is early preterm birth (<34 weeks).Key limitations: exploratory subgroup analysis · effect direction depends on baseline status · early preterm birth only, not <37 weeks
Confirms the benefit is restricted to low-status women.
“Omega-3 supplementation reduced the odds of EPTB for women with low total omega-3 status in early pregnancy (OR=0.30, 95% CI 0.10-0.93).”
Panel auditInternal validity: medium · scope of inference: Singleton pregnancies in the ORIP trial, identifying which subgroups benefit; speaks to subgroup effects rather than the average woman.Key limitations: exploratory multiple-subgroup analysis · benefit confined to subgroups · no overall effect reported
States directly that the flagship RCT found no overall effect.
“Based on complier average causal effects, n-3 supplementation reduced the risk of preterm birth in compliers (relative risk=0.76; 95% CI 0.60 to 0.97), but not early preterm birth (relative risk=0.80; 95% CI 0.44 to 1.46).”
Panel auditInternal validity: medium · scope of inference: ORIP singleton pregnancies, contrasting compliers and the overall intention-to-treat population; the reduction is a complier-conditional, not overall, estimate.Key limitations: no overall intention-to-treat effect · complier-conditional estimate · self-reported compliance
3 of 10 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The best evidence shows the effect is conditional on baseline status and subgroup rather than a reliable general reduction, so the unqualified claim is only partially carried by the corpus.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Prospective confirmation of the low baseline status benefit. The headline conditional effect is a post hoc subgroup result from one trial [1][3][4]; it needs prospective testing. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A double-blind RCT that enrols on measured baseline omega-3 status and prespecifies early preterm birth as the primary outcome.
Open question: Does omega-3 supplementation reduce preterm birth when treatment is restricted prospectively to women with low baseline omega-3 status? Why it is still open: The only supporting evidence is exploratory, post hoc biomarker stratification of a single trial [1][3][4].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19